Biogen Inc (BIIB) : Matterhorn Capital Management has sold out all of its stake in Biogen Inc during the most recent quarter, according to the disclosure filed by the company on Aug 2, 2016 with the SEC. The investment management company has sold out 7,522 shares of Biogen Inc which is valued at $2,417,119.
Other Hedge Funds, Including , Parkside Financial Bank Trust reduced its stake in BIIB by selling 32 shares or 5.51% in the most recent quarter. The Hedge Fund company now holds 549 shares of BIIB which is valued at $176,416. Biogen Inc makes up approx 0.08% of Parkside Financial Bank Trust’s portfolio. Capital Fund Management S.a. added BIIB to its portfolio by purchasing 48,664 company shares during the most recent quarter which is valued at $14,032,264. Biogen Inc makes up approx 0.24% of Capital Fund Management S.a.’s portfolio.Robeco Institutional Asset Management B.v. boosted its stake in BIIB in the latest quarter, The investment management firm added 6,570 additional shares and now holds a total of 240,951 shares of Biogen Inc which is valued at $69,340,879. Biogen Inc makes up approx 0.51% of Robeco Institutional Asset Management B.v.’s portfolio.Trust Co Of Vermont boosted its stake in BIIB in the latest quarter, The investment management firm added 304 additional shares and now holds a total of 1,503 shares of Biogen Inc which is valued at $394,402. Biogen Inc makes up approx 0.05% of Trust Co Of Vermont’s portfolio.Daiwa Sb Investments Ltd. reduced its stake in BIIB by selling 5,480 shares or 84.05% in the most recent quarter. The Hedge Fund company now holds 1,040 shares of BIIB which is valued at $261,352. Biogen Inc makes up approx 0.07% of Daiwa Sb Investments Ltd.’s portfolio.
Biogen Inc closed down -2.31 points or -0.73% at $313.65 with 21,36,783 shares getting traded on Monday. Post opening the session at $316.02, the shares hit an intraday low of $309.16 and an intraday high of $316.35 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.
Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.